Journal
CANCERS
Volume 10, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/cancers10030072
Keywords
immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification
Categories
Funding
- JSPS [JP16K08679]
- Ministry of the Environment, Japan
- Grants-in-Aid for Scientific Research [16K08679] Funding Source: KAKEN
Ask authors/readers for more resources
Immunohistochemistry is a widely available technique that is less challenging and can provide clinically meaningful results quickly and cost-efficiently in comparison with other techniques. In addition, immunohistochemistry allows for the evaluation of cellular localization of proteins in the context of tumor structure. In an era of precision medicine, pathologists are required to classify lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted therapies. This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma. Major pitfalls in evaluating immunohistochemical results are also described.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available